Moderate to Severe Plaque Psoriasis Clinical Trials in Frankfurt am Main
2 recruitingFrankfurt am Main, Germany
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL168 enrolled50 locationsNCT06425549
Recruiting
Phase 3
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
Psoriatic ArthritisModerate to Severe Plaque Psoriasis
UCB Biopharma SRL90 enrolled16 locationsNCT06506916